Evidence map›Paper›PMID 33670766›Full record

ArticleInternational journal of molecular sciences2021

Extensive Histopathological Characterization of Inflamed Bowel in the Dextran Sulfate Sodium Mouse Model with Emphasis on Clinically Relevant Biomarkers and Targets for Drug Development.

Rita Bonfiglio, Filippo Galli, Michela Varani, Manuel Scimeca, Filippo Borri, Sara Fazi, Rosella Cicconi, Maurizio Mattei, Giuseppe Campagna, Tanja Schönberger and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. A NovelPharmaceutics · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Radioimmune Imaging of αPharmaceutics · 2023
    Article
  10. Article
  11. OralPharmaceutics · 2022
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Rita BonfiglioDepartment of Experimental Medicine, University "Tor Vergata", via Montpellier 1, 00133 Rome, Italy.
Filippo GalliNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-3439-6010
Michela VaraniNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-7766-9031
Manuel ScimecaDepartment of Experimental Medicine, University "Tor Vergata", via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0003-0585-1309
Filippo BorriUOC Anatomia Patologica, Department of Oncology, USL Toscana Sud-Est, San Donato Hospital, 52100 Arezzo, Italy.ORCID 0000-0002-5631-0724
Sara FaziDepartment of Experimental Medicine, University "Tor Vergata", via Montpellier 1, 00133 Rome, Italy.
Rosella CicconiInterdepartmental Center for Comparative Medicine, Alternative Techniques and Aquaculture (CIMETA), University of Rome "Tor Vergata", via Montpellier 1, 00133 Rome, Italy.ORCID 0000-0002-9983-8772
Maurizio MatteiInterdepartmental Center for Comparative Medicine, Alternative Techniques and Aquaculture (CIMETA), University of Rome "Tor Vergata", via Montpellier 1, 00133 Rome, Italy.
Giuseppe CampagnaNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0002-1884-9171
Tanja SchönbergerDivison of Target Discovery Research and Target Validation Technologies, Boehringer Ingelheim Pharma GmbH & Co. KG, 88387 Biberach an der Riss, Germany.
Ernest RaymondImmunology and Respiratory Department, Boehringer Ingelheim Pharma GmbH & Co. KG, Ridgefield, CT 06877, USA.
Andreas WunderDivision of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88387 Biberach an der Riss, Germany.
Alberto SignoreNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, 00161 Rome, Italy.ORCID 0000-0001-8923-648X
Elena BonannoDepartment of Experimental Medicine, University "Tor Vergata", via Montpellier 1, 00133 Rome, Italy.
University of Rome Tor Vergata · ITSapienza University of Rome · ITBoehringer Ingelheim (Germany) · DEBoehringer Ingelheim (United States) · USOspedale San Donato · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to develop a reliable and reproducible inflammatory bowel disease (IBD) murine model based on a careful spatial-temporal histological characterization. Secondary aims included extensive preclinical studies focused on the in situ expression of clinically relevant biomarkers and targets involved in IBD. C57BL/6 female mice were used to establish the IBD model. Colitis was induced by the oral administration of 2% Dextran Sulfate Sodium (DSS) for 5 days, followed by 2, 4 or 9 days of water. Histological analysis was performed by sectioning the whole colon into rings of 5 mm each. Immunohistochemical analyses were performed for molecular targets of interest for monitoring disease activity, treatment response and predicting outcome. Data reported here allowed us to develop an original scoring method useful as a tool for the histological assessment of preclinical models of DSS-induced IBD. Immunohistochemical data showed a significant increase in TNF-α, α4β7, VEGFRII, GR-1, CD25, CD3 and IL-12p40 expression in DSS mice if compared to controls. No difference was observed for IL-17, IL-23R, IL-36R or F480. Knowledge of the spatial-temporal pattern distribution of the pathological lesions of a well-characterized disease model lays the foundation for the study of the tissue expression of meaningful predictive biomarkers, thereby improving translational success rates of preclinical studies for a personalized management of IBD patients.

Indexed as

Drug DevelopmentAnimalsBiomarkersColitisCytokinesDextran SulfateDisease Models, AnimalFemaleInflammatory Bowel DiseasesIntegrinsIntestinal MucosaMiceMice, Inbred C57BLVascular Endothelial Growth Factor Receptor-2BiomarkersCytokinesDextran Sulfateintegrin alpha4beta7IntegrinsVascular Endothelial Growth Factor Receptor-2biomarker discoverydextran sulfate sodium mousehistopathologyinflammatory bowel diseasepreclinical model

Identifiers

PMID33670766
PMCPMC7923003
OpenAlexW3129872098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.